From: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
Research group
Control group
P
Progress
0.080
CR
2 (4.4%)
0 (0.0%)
PR
26 (57.8%)
17 (37.8%)
SD
9 (20.0%)
15 (33.3%)
PD
8 (17.8%)
13 (28.9%)
RR
28 (62.2%)
0.035
DCR
37 (82.2%)
32 (71.1%)
0.319